AVANIR Pharmaceuticals Income Statement
View: Annual | Quarterly
This data is provided as per license from EDGAR Online
| Sep 07 | Sep 06 | Sep 05 | |
|---|---|---|---|
| Revenue | 9.2 | 15.2 | 16.7 |
| Cost of Goods Sold | 4.7 | 7.9 | 0.0 |
| Gross Profit | 4.6 | 7.3 | -- |
| Gross Profit Margin | 49.6% | 47.9% | 0.0% |
| SG&A Expense | 30.7 | 63.3 | 45.9 |
| Depreciation & Amortization | 3.3 | 4.0 | 1.9 |
| Operating Income | (29.4) | (60.0) | (31.1) |
| Operating Margin | -- | -- | -- |
| Nonoperating Income | 2.2 | 1.8 | 0.6 |
| Nonoperating Expenses | 1.3 | 0.8 | 0.1 |
| Income Before Taxes | (28.4) | (58.9) | (30.6) |
| Income Taxes | 0.0 | 0.0 | 0.0 |
| Net Income After Taxes | (28.4) | (58.9) | (30.6) |
| Continuing Operations | (28.4) | (58.9) | (30.6) |
| Discontinued Operations | 7.4 | -- | -- |
| Total Operations | (20.9) | (58.9) | (30.6) |
| Total Net Income | (20.9) | (62.5) | (30.6) |
| Net Profit Margin | -- | -- | -- |
| Diluted EPS from Total Net Income ($) | (0.53) | (2.04) | (1.20) |
| Dividends per Share | -- | -- | -- |
This data is provided as per license from EDGAR Online
